Peripheral T-cell lymphoma, not otherwise specified

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of diseases.
• Current standard first-line treatment involves anthracycline-containing regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP).
• Autologous stem cell transplantation can improve long-term survival for responders, but many patients are ineligible or experience relapse.

Purpose of the Study:

• To review the current treatment landscape for PTCL-NOS.
• To discuss the efficacy and limitations of newly approved agents for relapsed/refractory PTCL.
• To explore the potential of novel drug combinations to improve treatment outcomes.

Main Methods:

• Review of current literature on PTCL-NOS treatment.
• Analysis of approved therapies for relapsed and refractory PTCL.
• Discussion of ongoing clinical investigations for novel agents and combination regimens.

Main Results:

• Approved agents like pralatrexate, romidepsin, belinostat, and brentuximab vedotin demonstrate activity in relapsed/refractory PTCL.
• These agents have not significantly improved overall survival rates.
• Treatment refractoriness and early relapse remain significant challenges in PTCL management.

Conclusions:

• Novel agents offer therapeutic options for relapsed/refractory PTCL but do not overcome the survival limitations of current standards.
• Investigating the incorporation of new drugs into the CHOP backbone is crucial.
• Combination therapies aim to enhance response rates, increase transplant eligibility, and prolong survival in PTCL patients.